Valuation: Erasca, Inc.

Market Cap 6.38B 5.54B 5.17B 4.75B 8.97B 607B 9.07B 60.9B 23.81B 303B 23.96B 23.43B 1,005B P/E 2026 *
-19.3x
P/E 2027 * -32.3x
Enterprise Value 5.86B 5.09B 4.74B 4.36B 8.24B 557B 8.33B 55.93B 21.86B 279B 22.01B 21.52B 923B EV / Sales 2026 *
-
EV / Sales 2027 * 11,609x
Free-Float
90.32%
Yield 2026 *
-
Yield 2027 * -
1 day+0.60%
1 week+3.10%
Current month+0.66%
1 month-3.08%
3 months+82.88%
6 months+53.79%
Current year+391.13%
1 week 17.08
Extreme 17.08
19
1 month 17.08
Extreme 17.08
21.6
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2019
Director of Finance/CFO 43 06/01/2021
Chief Tech/Sci/R&D Officer - 24/05/2022
Director TitleAgeSince
Chairman 54 30/09/2018
Director/Board Member 79 31/05/2018
Director/Board Member 58 01/07/2018
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Free

Director

29,888 0.0096%
29/01/26 Free

General Counsel

560,000 0.1974%
29/01/26 Free

Chief Executive Officer

2,000,000 0.7049%
Change 5-day change 1-year change 3-year change Capi.($)
+0.08%+3.10%+1,118.00%+597.33% 6.38B
+0.36%-2.85%+0.14%+13.91% 48B
+0.54%+7.20%+405.22%+554.37% 41.13B
+2.70%-4.79%+28.15%+7.48% 37.56B
+2.21%+0.78%+7.34%+75.86% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
+0.04%-2.71% - - 16.12B
+1.15%+0.12%+34.22%+124.90% 16.05B
+1.22%+1.69%+4.80%+18.87% 13.76B
+4.05%-7.98%-1.21%-34.82% 12.1B
Average +1.82%-1.81%+179.06%+155.85% 25.69B
Weighted average by Cap. +1.78%-1.23%+108.71%+139.00%

Financials

2026 *2027 *
Net sales - 500K 434K 405K 372K 703K 47.56M 711K 4.77M 1.87M 23.78M 1.88M 1.84M 78.78M
Net income -299M -259M -242M -222M -420M -28.4B -425M -2.85B -1.11B -14.2B -1.12B -1.1B -47.04B -191M -166M -155M -142M -269M -18.19B -272M -1.83B -713M -9.09B -718M -702M -30.13B
Net Debt -520M -452M -421M -387M -732M -49.49B -740M -4.97B -1.94B -24.74B -1.95B -1.91B -81.97B -576M -500M -466M -428M -810M -54.76B -819M -5.49B -2.15B -27.37B -2.16B -2.11B -90.7B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
05/08/26 US$18.47 +0.49% 779,964
04/08/26 US$18.38 +3.03% 4,759,060
03/08/26 US$17.84 -1.71% 2,751,851
31/07/26 US$18.15 -2.84% 2,696,841
30/07/26 US$18.68 +5.42% 3,699,720
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.38USD
Average target price
22.80USD
Spread / Average Target
+24.05%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock